Business context and reporting period
The Joint Corp. filed this Form 10-K for the fiscal year ended December 31, 2022; it is an annual report, not a standalone fourth-quarter report. The company operates and franchises cash-based, appointment-free chiropractic clinics. At year-end, it had 838 clinics: 712 franchised and 126 company-owned or managed. System-wide sales were $435.3 million, a non-GAAP measure that includes franchisee sales; company-reported revenue was $101.9 million.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $101.9 million | $80.9 million |
| Operating income | $2.1 million | $5.4 million |
| Net income | $1.2 million | $6.6 million |
| Basic / diluted EPS | $0.08 / $0.08 | $0.46 / $0.44 |
| Operating cash flow | $11.1 million | $15.2 million |
| Adjusted EBITDA (non-GAAP) | $11.5 million | $12.6 million |
- Revenue increased 26.0%; company-owned or managed clinic revenue grew 34.0% to $59.4 million, while franchise operations revenue rose to $42.5 million.
- Operating margin fell to about 2.0% from 6.6%; net margin fell to about 1.2% from 8.1%. General and administrative expense increased 37.5% to $68.0 million, led by payroll and related costs.
- System-wide sales grew 21%; comparable sales rose 9% for clinics open at least 13 months and 4% for clinics open at least 48 months.
- Cash and cash equivalents were $9.7 million at year-end, down from $19.5 million; restricted cash was $0.8 million. Operating cash flow was more than offset by $20.8 million of investing outflows, principally clinic acquisitions, capital expenditures, and regional developer rights repurchases.
- Debt under the credit agreement was $2.0 million. The amended revolving facility has a $20.0 million commitment, plus a $30.0 million uncommitted additional amount; the development line was terminated. The company reported covenant compliance. Operating lease liabilities totaled $24.0 million, with $27.1 million of undiscounted operating lease payments.
- Management said existing cash, expected operating cash flow, and available financing should fund anticipated needs for at least 12 months, while noting acquisitions and macroeconomic uncertainty could affect liquidity. No dividends are expected in the foreseeable future.
Material changes, outlook, and unusual items
- Revenue growth did not translate into higher earnings: operating income declined 61.2% and net income declined 82.1%, reflecting higher clinic and corporate costs, including wage inflation and expansion-related expenses. The corporate clinics segment swung from $4.4 million operating income to a $0.9 million loss; franchise operations operating income increased to $19.6 million.
- The company acquired or developed clinics and repurchased regional developer rights during 2022. It ended the year with 197 sold clinic licenses not yet developed and letters of intent for 38 more. Management’s stated strategy is continued franchise expansion and selective development and acquisition of company-owned or managed clinics. The filing does not provide specific 2023 revenue or earnings guidance.
- Management anticipated a volatile 2023 macroeconomic environment and elevated cost inflation, particularly labor costs; pricing actions may partly offset these pressures. Labor shortages have limited clinic hours and growth and reduced revenue. Inflation, higher interest rates, weaker discretionary spending, competition, and delays in clinic development are key operating risks.
- In March 2023, the company received notice of a $4.8 million employee retention credit, plus interest. The credit is subject to IRS audit for five years, and 20% is payable as a consulting fee; repayment risk could therefore leave unrecoverable consulting costs.
- A $750,000 employee-related claim was settled in February 2022; after a $250,000 insurance recovery, the $500,000 net impact was recorded in 2021. A 2022 impairment charge of approximately $0.2 million related to a closed clinic lease asset; no goodwill impairment was recorded.
- A marketing vendor breach in November 2022 exposed certain patient and employee contact and birthdate information. The company said it did not believe the incident had a material adverse effect; notification obligations in two states were still being assessed.
- Previously reported material weaknesses in internal controls were reported remediated as of December 31, 2022. Management concluded controls were effective; the external auditor did not attest to internal-control effectiveness.
- Key structural risks include state restrictions on corporate practice of chiropractic and fee-splitting, evolving franchise and joint-employer rules, franchisee performance, labor availability, data security, and the discretionary nature of maintenance care. The auditor issued an unqualified opinion on the financial statements and identified valuation growth-rate assumptions for acquired intangible assets as a critical audit matter.
Important facts for investors to verify
- Whether clinic-level revenue growth and comparable-sales trends can offset labor, marketing, and corporate costs and restore margins.
- Whether the company can recruit chiropractors and open its substantial pipeline of sold or proposed clinic licenses on schedule.
- Actual cash availability under the revolving facility, covenant headroom, and funding needs for leases, acquisitions, and new clinics.
- The IRS’s final determination on the $4.8 million employee retention credit, including any repayment exposure and the consulting fee.
- Developments in state chiropractic-practice regulation, joint-employer standards, franchise regulation, and the vendor data-breach response.